Collection of Samples USOPTIVAL Study
Part of paid clinical trials in Chula Vista, California.
- Sponsor
- Universal Diagnostics
- Study ID
- NCT04792684
- Status
- Recruiting
Conditions
- Advanced Adenomas (AA)
- Colorectal Cancer (CRC)
Eligibility Criteria
- Sex
- ALL
- Age
- 45 Years - 84 Years
- Healthy Volunteers
- Accepted
Interventions
- Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel — DIAGNOSTIC_TESTEvaluate the performance of a preliminary panel of biomarkers
Study Details
A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.
Key Dates
- Start date
- Dec 30, 2020
- Status verified
- Nov 2025
- Primary completion
- Dec 30, 2025
- Completion
- Dec 30, 2025
Study Design
- Enrollment
- 1,300 participants (estimated)
Arms
- Arm: Arm A.Subjects that have a suspected advanced adenoma or have been newly diagnosed with CRC still not resected and scheduled for surgery
- Arm: Arm BSubjects at average-risk for CRC and scheduled for CRC screening colonoscopy
Primary Outcome Measure
Samples Collected for Plasma Circulating Free-DNA (cfDNA) Marker Testing [ Time Frame: Within 12 months of sample collection ]
Central Contacts
- Antonio Jesus Merino Calvo(+34)674945571
Locations (16)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Precision Recearch Institute | Chula Vista | California | 91910 | - |
| Medical Associates Research Group | San Diego | California | 92123 | - |
| Precision Research Institute | San Diego | California | 92114 | - |
| Clinical Research of California | Walnut Creek | California | 94598 | - |
| Center for Gastrointestinal Disorders | Hollywood | Florida | 33021 | - |
| Lakeland Regional Cancer Center | Lakeland | Florida | 33805 | Manuel Molina |
| Springfield Clinic | Springfield | Illinois | 62702 | Peter Hofmann |
| Ochsner Clinic | New Orleans | Louisiana | 70121 | - |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | - |
| Mid Hudson Medical Research | New Windsor | New York | 12553 | Sashi Makam |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | - |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | Bryson Katona |
| Frontier Clinical Research | Uniontown | Pennsylvania | 15401 | - |
| Clinical Trials Network | Union City | Tennessee | 38261 | - |
| Vilo Research Group | Houston | Texas | 77017 | - |
| Gastroenterology Consultants of SW Virginia | Raonoke | Virginia | 24014 | - |
Find similar trials in Chula Vista, CA
Related Studies
- TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid TumorsPHASE1/PHASE2 · Recruiting · Portage Biotech · Los Angeles, California
- Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsPHASE1 · Recruiting · Exelixis · Phoenix, Arizona
- Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASPHASE1/PHASE2 · Recruiting · Revolution Medicines, Inc. · Orange, California
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)PHASE1/PHASE2 · Recruiting · GI Innovation, Inc. · Scottsdale, Arizona